Related Experiment Video
Updated: Jul 26, 2026
07:50
Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer
Published on: September 18, 2020
6.2K
Methylation markers differentiate thyroid cancer from benign nodules.
J K Stephen1, K M Chen2, J Merritt2
1Department of Otolaryngology/Head and Neck Research, Henry Ford Hospital, 1 Ford Place, 1D-06, Detroit, MI, 48202, USA. jstephe2@hfhs.org.
Journal of Endocrinological Investigation
|June 15, 2017
Summary
Identifying DNA methylation markers can help differentiate thyroid cancer (TC) from benign nodules. Gene panels show promise in distinguishing subtypes, potentially reducing overdiagnosis and unnecessary surgeries.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Thyroid cancer (TC) incidence is rising globally.
- Distinguishing TC from benign nodules via cytology alone is challenging, especially for certain subtypes.
- Need for molecular markers for accurate diagnosis and subtyping.
Purpose of the Study:
- Identify DNA methylation markers for early TC detection.
- Molecularly differentiate TC subtypes from benign nodules.
- Assess the clinical utility of gene methylation panels.
Main Methods:
- Examined promoter methylation of 21 candidate genes in FFPE tissues using QMSP.
- Analyzed a cohort of 329 patients with normal thyroid, benign nodules (FA), follicular TC (FTC), and papillary TC (PTC).
- Utilized logistic regression models to identify optimal gene combinations for group separation.
Main Results:
- Combination gene panels demonstrated ability to discriminate between FTC and FA, and FTC and normal thyroid tissue.
- TSHR methylation distinguished papillary TC (PTC) from FTC and FA.
- A six-gene panel (TIMP3, RARB2, SERPINB5, RASSF1, TPO, TSHR) showed high sensitivity (91%) and specificity (81%) in differentiating PTC from normal thyroid tissue.
Conclusions:
- Aberrant gene methylation panels show clinical potential for differentiating TC subtypes from benign nodules.
- These molecular markers could aid in reducing TC overdiagnosis.
- Further validation in additional studies is warranted to confirm these findings for clinical application.
